This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
AN INTERNATIONAL panel of asthma experts is advising physicians to adopt a sweeping philosophical change in the way they manage asthma. Treat asthma not as an episodic, bronchospastic disorder, they suggest, but as a chronic, persistent disease with inflammation at its core.
That is the word from the International Asthma Management Project, a working group of 18 physicians and scientists convened by the National Heart, Lung, and Blood Institute, Bethesda, Md, in their now-released report on the diagnosis and management of asthma.
In what is termed an international consensus, the report recommends regular use of anti-inflammatory drugs, preferably inhaled corticosteroids, as first-line therapy for anything more than occasional mild asthma. β2-Agonist bronchodilators, commonly used in the United States as regularly scheduled, first-line therapy, are endorsed only for the pretreatment of exercise-induced asthma and for the symptomatic relief of acute exacerbations, or "asthma attacks," when anti-inflammatory therapy is insufficient.
Randall T. International Consensus Report Urges Sweeping Reform in Asthma Treatment. JAMA. 1992;267(16):2153-2154. doi:10.1001/jama.1992.03480160011002